Literature DB >> 9206979

Inhibition of the HIV Rev transactivator : a new target for therapeutic intervention.

A Heguy1.   

Abstract

The viral transactivator Rev is essential for HIV replication, since it allows the nuclear export of unspliced and partially spliced viral mRNAs that encode the structural proteins. Rev is an RNA binding protein that interacts with a highly structured RNA element, the RRE, found within the envelope sequences. This viral protein also interacts with cellular proteins, termed nucleoporins, and acts as an adaptor between the viral mRNAs and the cellular nuclear export machinery. Both interactions are specific, and required for Rev function. Because of its crucial role in the HIV replication cycle, and its novel mechanism of action, Rev represents an ideal target for therapeutic intervention. This review describes the efforts towards Rev inhibition. Gene therapy approaches, including the expression of trans-dominant mutants and RNA decoys, as well as antisense therapies and small molecule inhibitors of Rev-RRE binding or Rev interaction with the cellular machinery will be discussed

Mesh:

Substances:

Year:  1997        PMID: 9206979     DOI: 10.2741/a191

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  7 in total

1.  Fluorescent ribonucleoside as a FRET acceptor for tryptophan in native proteins.

Authors:  Yun Xie; Tucker Maxson; Yitzhak Tor
Journal:  J Am Chem Soc       Date:  2010-09-01       Impact factor: 15.419

2.  Rev inhibition strongly affects intracellular distribution of human immunodeficiency virus type 1 RNAs.

Authors:  Dusan Cmarko; Stig-Ove Bøe; Catia Scassellati; Anne Marie Szilvay; Svend Davanger; Xiang-Dong Fu; Gunnar Haukenes; Karl-Henning Kalland; Stanislav Fakan
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

3.  Heterocyclic compounds that inhibit Rev-RRE function and human immunodeficiency virus type 1 replication.

Authors:  Deidra Shuck-Lee; Fei Fei Chen; Ryan Willard; Sharmila Raman; Roger Ptak; Marie-Louise Hammarskjold; David Rekosh
Journal:  Antimicrob Agents Chemother       Date:  2008-07-14       Impact factor: 5.191

Review 4.  Molecular strategies to inhibit HIV-1 replication.

Authors:  Morten Hjuler Nielsen; Finn Skou Pedersen; Jørgen Kjems
Journal:  Retrovirology       Date:  2005-02-16       Impact factor: 4.602

5.  Long lasting control of viral rebound with a new drug ABX464 targeting Rev - mediated viral RNA biogenesis.

Authors:  Noëlie Campos; Renier Myburgh; Aude Garcel; Audrey Vautrin; Laure Lapasset; Erika Schläpfer Nadal; Florence Mahuteau-Betzer; Romain Najman; Pauline Fornarelli; Katjana Tantale; Eugénia Basyuk; Martial Séveno; Julian P Venables; Bernard Pau; Edouard Bertrand; Mark A Wainberg; Roberto F Speck; Didier Scherrer; Jamal Tazi
Journal:  Retrovirology       Date:  2015-04-09       Impact factor: 4.602

6.  A novel retroviral vector system to analyze expression from mRNA with retained introns using fluorescent proteins and flow cytometry.

Authors:  Patrick E H Jackson; Jing Huang; Monika Sharma; Sara K Rasmussen; Marie-Louise Hammarskjold; David Rekosh
Journal:  Sci Rep       Date:  2019-04-23       Impact factor: 4.379

7.  A Transcription Factor Regulates Gene Expression in Chloroplasts.

Authors:  Kexing Xin; Ting Pan; Shan Gao; Shunping Yan
Journal:  Int J Mol Sci       Date:  2021-06-24       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.